Pouwels Sjaak, Johannes Emschka, Scarano-Pereira Juan Pablo
Department of Surgery, Campus Detmold, Klinikum Lippe, Bielefeld University, 32756 Detmold, Germany.
Department of Intensive Care Medicine, Elisabeth-Tweesteden Hospital, 5022 GC Tilburg, The Netherlands.
Medicina (Kaunas). 2025 Apr 7;61(4):680. doi: 10.3390/medicina61040680.
: Out-of-hospital cardiac arrest (OHCA) is a common manifestation of heart disease and a leading cause of death in western societies with an overall survival rate of 10%. Guidelines generally prefer the peripheral intravenous (IV) access as the first option for OHCA patients, leaving the intraosseous (IO) route for patients in which IV access is not feasible or unsuccessful. This systematic review will purely focus on the clinical differences between adrenaline administered via the IO route compared to the IV route and its effects on morbidity and mortality after OHCA. : A multi-database (PubMed, Medline, Embase, and The Cochrane Library) was performed and was searched between the earliest date of each database and 16 February 2024. For data extraction, a structured checklist was used, including type of study, the number of patients, age, gender, Return of Spontaneous Circulation (ROSC), associated morbidity, mortality, neurological, and general outcome. : The initial literature search produced 1772 results. After screening for title and abstract, a total of nine studies were included in our systematic review. Of these studies, six were retrospective cohort studies, one prospective study, and two sub-analyses of previous randomized trials. Due to significant heterogeneity, a meta-analysis was not performed. : In our systematic review we have found a small number of studies comparing IV and IO adrenaline administration during cardiac arrest. Due to significant heterogeneity, a meta-analysis was not performed and no firm conclusions could be drawn about which route of adrenalin administration leads to better outcomes.
院外心脏骤停(OHCA)是心脏病的常见表现,也是西方社会主要的死亡原因之一,总体生存率为10%。指南通常倾向于将外周静脉(IV)通路作为OHCA患者的首选,而对于IV通路不可行或未成功的患者则采用骨内(IO)通路。本系统评价将仅关注经IO途径与IV途径给予肾上腺素的临床差异及其对OHCA后发病率和死亡率的影响。
进行了多数据库检索(PubMed、Medline、Embase和Cochrane图书馆),检索时间为每个数据库的最早日期至2024年2月16日。数据提取采用结构化清单,包括研究类型、患者数量、年龄、性别、自主循环恢复(ROSC)、相关发病率、死亡率、神经学和总体结局。
初步文献检索产生了1772条结果。经过标题和摘要筛选,共有9项研究纳入我们的系统评价。其中,6项为回顾性队列研究,1项为前瞻性研究,2项为既往随机试验的亚分析。由于显著的异质性,未进行荟萃分析。
在我们的系统评价中,我们发现少数研究比较了心脏骤停期间IV和IO途径给予肾上腺素的情况。由于显著的异质性,未进行荟萃分析,因此无法就哪种肾上腺素给药途径能带来更好的结局得出确凿结论。